A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Latest Information Update: 20 Dec 2024
Price :
$35 *
At a glance
- Drugs NS 229 (Primary) ; Prednisolone; Prednisone
- Indications Churg-Strauss syndrome
- Focus Therapeutic Use
- Sponsors NS Pharma
- 22 Jul 2024 Planned End Date changed from 1 May 2025 to 1 Jul 2026.
- 22 Jul 2024 Planned primary completion date changed from 1 Apr 2025 to 1 Jun 2026.
- 16 Feb 2024 Status changed from not yet recruiting to recruiting.